Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Caris Life Sciences (CAI) EPS (Weighted Average and Diluted) (2024 - 2025)

Caris Life Sciences (CAI) has 2 years of EPS (Weighted Average and Diluted) data on record, last reported at $1.61 in Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 193.06% year-over-year to $1.61; the TTM value through Dec 2025 reached $5.26, changed N/A, while the annual FY2025 figure was -$3.22, 69.79% up from the prior year.
  • EPS (Weighted Average and Diluted) reached $1.61 in Q4 2025 per CAI's latest filing, down from $7.97 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $7.97 in Q3 2025 and bottomed at -$10.27 in Q2 2025.